Health Condition 1: L237- Allergic contact dermatitis due toplants, except food
Conditions
Interventions
Intervention1: Oral Tofacitinib: Tofacitinib is an oral JAK 1/3 inhibitor which has been approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease and has
Sponsors
AIIMS, New Delhi
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with airborne contact dermatitis with positive patch test to Parthenium, having a Parthenium Dermatitis Severity Score (PDSS) of more than or equal to 10. 2. Patients more than or equal to 18 years of age. 3. Consenting patients who are willing to undergo treatment and report for follow up.
Exclusion criteria
Exclusion criteria: 1. Patients with significant and active liver, renal or haematological disease. 2. Patients 3. Pregnant and lactating females. 4. Patients with active or latent TB. 5. Patients with a lymphocyte count less than 500 cells/mm3, an absolute neutrophil count less than 1000 cells/mm3, or hemoglobin level less than 9 g/dL. 6. Patients with active infections. 7. Patients with history of thromboembolic phenomenon or on anticoagulants 8. Patients on immunosuppressive therapy in the last 4 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To study the effectiveness & safety of oral tofacitinib in patients with Parthenium dermatitis.Timepoint: baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| To study the effect of tofacitinib on the patch test positivity in patients with Parthenium dermatitis.Timepoint: 0,4,8,12,16,20,24 weeks | — |
Countries
India
Contacts
Public ContactKaushal K Verma
AIIMS, New Delhi
Outcome results
None listed